AbbVie reports Q2 2026 earnings and revenue beats as Skyrizi and Rinvoq drive strong immunology sales growth.
Stock Earnings Results
July 31, 2026
Table of Contents
July 31, 2026
AbbVie Inc. (NYSE: ABBV) reported second-quarter 2026 results above expectations, supported by higher revenue, adjusted EPS growth, strong immunology and neuroscience sales, pipeline progress, and continued momentum from Skyrizi and Rinvoq.
AbbVie is a global biopharmaceutical company focused on immunology, neuroscience, oncology, aesthetics, eye care, and other therapeutic areas through its pharmaceutical and Allergan Aesthetics portfolios.
The company reported adjusted diluted EPS of $3.65, above estimates of $3.64, representing a 0.3% earnings surprise. Revenue came in at $16.99 billion, above estimates of $16.81 billion, with revenue growth of 10.2%.
Worldwide net revenue increased 10.2% year-over-year to $16.99 billion.
On an operational basis, revenue increased 9.5%.
GAAP diluted EPS was $2.03, up from $0.52 in the prior-year quarter.
Adjusted diluted EPS was $3.65, up 22.9%.
The adjusted EPS result included an unfavorable $0.17 per share impact from acquired IPR&D and milestones expense.
GAAP operating margin was 37.9%.
Adjusted operating margin was 48.3%.
Global immunology revenue increased 15.1% year-over-year to $8.79 billion.
Skyrizi revenue increased 24.4% to $5.51 billion.
Rinvoq revenue increased 24.5% to $2.53 billion.
Humira revenue declined 35.9% to $756 million.
The quarter showed that Skyrizi and Rinvoq continue to offset the ongoing decline in Humira after biosimilar competition.
Global neuroscience revenue increased 20.3% to $3.23 billion.
Vraylar revenue increased 18.9% to $1.07 billion.
Botox Therapeutic revenue increased 12.2% to $1.04 billion.
Ubrelvy revenue increased 16.0% to $392 million.
Qulipta revenue increased 30.9% to $350 million.
Vyalev revenue was $256 million.
The neuroscience portfolio remained one of AbbVie’s strongest growth areas, helped by psychiatric treatment, migraine therapies, Botox Therapeutic, and Parkinson’s disease therapy Vyalev.
Global oncology revenue declined 1.5% to $1.65 billion.
Venclexta revenue increased 11.6% to $771 million.
Imbruvica revenue declined 29.4% to $532 million.
Elahere revenue increased 33.1% to $211 million.
Global aesthetics revenue increased 0.3% to $1.28 billion.
Botox Cosmetic revenue increased 5.2% to $728 million.
Juvederm revenue declined 6.0% to $245 million.
The results showed growth in Venclexta, Elahere, and Botox Cosmetic, but continued pressure from Imbruvica and Juvederm.
AbbVie reported several regulatory and clinical updates during the quarter.
The FDA and European Commission approved Skyrizi for children six years and older with moderate to severe plaque psoriasis.
The FDA also approved Skyrizi for pediatric use in psoriatic arthritis.
The European Commission approved Rinvoq for non-segmental vitiligo and severe alopecia areata.
The FDA approved Decnupaz for adult patients with blastic plasmacytoid dendritic cell neoplasm.
AbbVie also reported progress across oncology, gastroenterology, migraine, hematology, and aesthetics.
AbbVie announced a definitive agreement to acquire Apogee Therapeutics.
The deal values Apogee at approximately $10.9 billion.
The acquisition would add clinical-stage immunology assets, including zumilokibart, a late-stage IL-13 antibody for atopic dermatitis.
It also includes APG273, a long-acting combination candidate targeting IL-13 and TSLP in asthma.
AbbVie said the deal strengthens its immunology portfolio and is expected to close in the third quarter of 2026.
AbbVie updated its full-year 2026 adjusted diluted EPS guidance.
The company now expects adjusted diluted EPS of $13.87 to $14.07.
That compares with the prior range of $13.91 to $14.11.
The update includes a $0.14 per share dilutive impact from the proposed Apogee acquisition, partly offset by $0.10 of overperformance.
AbbVie said year-to-date acquired IPR&D and milestones expense had an unfavorable $0.58 per share impact through the second quarter.
AbbVie delivered another solid quarter as its post-Humira transition continued.
Revenue beat expectations, adjusted EPS came in slightly above estimates, immunology grew 15%, and neuroscience grew more than 20%. Skyrizi and Rinvoq remained the key growth engines, while Humira continued to decline and oncology results were mixed.
The key question is whether AbbVie can keep scaling newer immunology and neuroscience products while using acquisitions like Apogee to extend long-term growth.
Platforms like LevelFields track layoffs, market catalyst, activist investors, leadership changes, dividend increases, margin expansion, and stock reactions together, helping investors identify when biopharma stocks are moving on real operating momentum.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE